Macut underlined that Hemofarm is one of Serbia’s most important companies and a strong pillar of domestic industry and the economy, noting that the company accounts for approximately 4.5% of Serbia’s total industrial production and 93% within its sector.
According to him, this clearly demonstrates the company’s strength, the industrial base and the expertise that Serbia has, while exports, which grew by more than 62% in 2025 alone, confirm Hemofarm’s competitiveness on the international market.
He noted that the Serbian government supports investment, modernisation and industrial development, and called on other companies to follow Hemofarm’s example and contribute to making Serbia a competitive, innovative and strong economy.
Macut also highlighted the importance of opening a new Hemofarm facility in Šabac, given the significance of establishing stable availability of medicines in Serbia and continuous investment in the pharmaceutical sector.
The Prime Minister stated that the presence of large and technologically advanced companies such as Hemofarm contributes to economic stability and represents an important signal for further investment in Serbia.
The state will, as he pointed out, continue to support companies that develop high value-added production and strengthen the competitiveness of the Serbian economy.
The management of Hemofarm assessed the dialogue with government representatives as open and substantive, and confirmed their readiness to enhance cooperation in the coming period, including further development of capacities in Vršac and Šabac.